CEPI (the Coalition for Epidemic Preparedness Innovations) has unveiled a new collaboration with Profectus BioSciences and Emergent BioSolutions under which they will receive up to $36 million to advance the development and manufacture of a vaccine against the Lassa virus-an estimated 100,000 to 300,000 cases of Lassa virus infection occur each year, according to the U.S. CDC. Under the terms of the Framework Partnering Agreement for the collaboration among the three parties, Profectus will r...